Array BioPharma Inc

Array BioPharma Inc Stock Forecast & Price Prediction

Live Array BioPharma Inc Stock (ARRY) Price
$6.04

9

Ratings

  • Buy 8
  • Hold 1
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$6.04

P/E Ratio

61.85

Volume Traded Today

$19.7M

Dividend

Dividends not available for ARRY

52 Week High/low

20.15/5.56

Array BioPharma Inc Market Cap

$917.7M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $ARRY ๐Ÿ›‘

Before you buy ARRY you'll want to see this list of ten stocks that have huge potential. Want to see if ARRY made the cut? Enter your email below

ARRY Summary

Based on ratings from 9 stock analysts, the Array BioPharma Inc stock price is expected to increase by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Array BioPharma Inc. The lowest target is $7 and the highest is $22. Please note analyst price targets are not guaranteed and could be missed completely.

ARRY Analyst Ratings

About 9 Wall Street analysts have assignedARRY 8 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Array BioPharma Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ARRY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

ARRY stock forecast by analyst

These are the latest 20 analyst ratings of ARRY.

Analyst/Firm

Rating

Price Target

Change

Date

Colin Rusch
Oppenheimer

Outperform

$14

Maintains

Nov 8, 2024
Paul Coster
JP Morgan

Overweight

$15

Maintains

Nov 8, 2024
Philip Shen
Roth MKM

Neutral

$6

Maintains

Nov 8, 2024
Jon Windham
UBS

Buy

$10

Maintains

Nov 8, 2024
Joseph Osha
Guggenheim

Neutral


Downgrade

Nov 7, 2024
Kashy Harrison
Piper Sandler

Neutral

$7

Maintains

Oct 22, 2024
Paul Coster
JP Morgan

Overweight

$20

Maintains

Oct 17, 2024
Biju Perincheril
Susquehanna

Positive

$10

Maintains

Oct 16, 2024
Jordan Levy
Truist Securities

Buy

$10

Maintains

Oct 16, 2024
Ameet Thakkar
BMO Capital

Market Perform

$9

Maintains

Oct 14, 2024
Joseph Osha
Guggenheim

Buy

$12

Maintains

Oct 4, 2024
Christine Cho
Barclays

Overweight

$10

Maintains

Oct 3, 2024
Julien Dumoulin-Smith
Jefferies

Buy

$11

Upgrade

Sep 4, 2024
Tristan Richardson
Scotiabank

Sector Outperform

$12

Maintains

Aug 16, 2024
Joseph Osha
Guggenheim

Buy

$14

Maintains

Aug 16, 2024
Christine Cho
Barclays

Overweight

$11

Maintains

Aug 12, 2024
Jordan Levy
Truist Securities

Buy

$12

Maintains

Aug 12, 2024
Ameet Thakkar
BMO Capital

Market Perform

$11

Maintains

Aug 9, 2024
Colin Rusch
Oppenheimer

Outperform

$17

Maintains

Aug 9, 2024
Jon Windham
UBS

Buy

$16

Maintains

Aug 9, 2024

ARRY Company Information

What They Do: Manufactures solar tracking systems globally.

Business Model: The company generates revenue by manufacturing and selling advanced ground-mounting tracking systems used in solar energy projects. It operates through two segments, providing a variety of products that enhance energy production and reduce costs for solar installations.

Other Information: Array Technologies, Inc. has been operational since 1987 and is based in Albuquerque, New Mexico, serving markets in the United States, Spain, Brazil, Australia, and other international locations. Their innovative products, such as the DuraTrack HZ v3 and SmarTrack software, leverage machine learning to optimize solar energy production.
ARRY
Array BioPharma Inc (ARRY)

When did it IPO

2010

Staff Count

1,013

Country

United States

Sector/Industry

Technology/Solar

CEO

Mr. Kevin G. Hostetler

Market Cap

$917.7M

Array BioPharma Inc (ARRY) Financial Data

In 2023, ARRY generated $1.58B in revenue, which was a decrease of -3.72% from the previous year. This can be seen as a signal that ARRY's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$872.7M

Revenue From 2021

$853.3M

-2.22 %
From Previous Year

Revenue From 2022

$1.64B

91.90 %
From Previous Year

Revenue From 2023

$1.58B

-3.72 %
From Previous Year
  • Revenue TTM $982.2M
  • Operating Margin TTM 12.7%
  • Gross profit TTM $415.6M
  • Return on assets TTM 4.0%
  • Return on equity TTM -17.6%
  • Profit Margin -9.6%
  • Book Value Per Share 0.42%
  • Market capitalisation $917.7M
  • Revenue for 2021 $853.3M
  • Revenue for 2022 $1.64B
  • Revenue for 2023 $1.58B
  • EPS this year (TTM) $-0.98

Array BioPharma Inc (ARRY) Latest News

News Image

Thu, 07 Nov 2024

Sentiment - NEUTRAL

Source - Seeking Alpha

Summary - Array Technologies, Inc. will hold its Q3 2024 Earnings Conference Call on November 7, 2024, at 5:00 PM ET, featuring key executives and analysts from various financial institutions.

Why It Matters - The earnings call provides insight into Array Technologies' financial performance and future outlook, influencing investor sentiment and stock price movements.

News Image

Thu, 07 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - ARRAY Technologies reported Q3 2024 revenue of $231.4M and a gross margin of 33.8%. Net loss was $155.4M, including a $162M goodwill impairment. Adjusted EBITDA was $46.7M.

Why It Matters - ARRAY Technologies reported a significant net loss largely due to a non-cash impairment charge, despite positive adjusted EBITDA and gross margins. This mixed performance could affect investor sentiment and stock valuation.

News Image

Thu, 07 Nov 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Array Technologies, Inc. (ARRY) reported Q3 earnings of $0.17 per share, exceeding the Zacks estimate of $0.14 but down from $0.21 per share year-over-year.

Why It Matters - Array Technologies' earnings beat expectations, indicating operational strength, but the year-over-year decline may raise concerns about future growth and profitability.

News Image

Wed, 06 Nov 2024

Sentiment - NEGATIVE

Source - Market Watch

Summary - Trump may reverse green policies from the Biden administration, including solar tax credits and incentives from the Inflation Reduction Act, impacting investments in renewable energy.

Why It Matters - Changes in green policies could impact renewable energy investments, affecting market dynamics and stock performance in related sectors. Adjustments in tax credits may influence company valuations.

News Image

Mon, 04 Nov 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - Recent nuclear energy news has positively impacted the solar energy sector, indicating a potential shift in market dynamics.

Why It Matters - Nuclear energy developments can shift market dynamics, potentially boosting solar investments as alternatives, impacting energy sector valuations and investor sentiment.

News Image

Thu, 31 Oct 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Array Technologies (ARRY) may struggle to meet earnings expectations in its upcoming report due to lacking key performance indicators. Investors should prepare for this potential outcome.

Why It Matters - Array Technologies may underperform in its upcoming earnings report, signaling potential volatility or decline in stock value, impacting investor confidence and strategies.

...

ARRY Frequently asked questions

The highest forecasted price for ARRY is $22 from Christine Cho at Barclays.

The lowest forecasted price for ARRY is $7 from from Piper Sandler

The ARRY analyst ratings consensus are 8 buy ratings, 1 hold ratings, and 0 sell ratings.